<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/961708C6-9E60-4320-A114-532CD16A84CF"><gtr:id>961708C6-9E60-4320-A114-532CD16A84CF</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:surname>Walters</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E9A0F9D8-8AC1-427A-8715-60757CC9702B"><gtr:id>E9A0F9D8-8AC1-427A-8715-60757CC9702B</gtr:id><gtr:firstName>Harald</gtr:firstName><gtr:surname>Mischak</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000791"><gtr:id>F9A847AD-35D4-4FE3-97B9-36D3C21E9999</gtr:id><gtr:title>Development of an efficient, robust MS-based platform for early detection of acute kidney injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000791</gtr:grantReference><gtr:abstractText>Acute Kidney Injury (AKI) as a severe complication in hospitalized patients, a life-threatening complication that still has a high mortality. In addition, AKI is associated with high costs for intensive and prolongued treatment. To date, no early detection of AKI is possible. However, early detection is essential to initiate appropriate treatment, thereby preventing development of disease, or at least reducing the severity. Such an appproach would reduce mortality, and also costs. 
The proposal aims at developing a technology platform that enables early detection of AKI, based on specific proteins an peptides in urine, so-called biomarkers. These biomarkers have already been identified. For their efficient clinical application a plattform that allows accurate and fast analysis has to be developed, this development is the scope of the project. Upon successful completion of the project, a robust technology will be available that enables early detection of AKI, hence initiation of appropriate early therapeutic measures. We anticipate that as a result of this project, mortality due to AKI can be significantly decreased, and costs can be reduced.</gtr:abstractText><gtr:technicalSummary>Acute kidney injury (AKI) is a frequent and serious condition in critically-ill patients, increasing mortality rate independent of other risk factors. Currently, serum creatinine is monitored to detect AKI; this is an inadequate test, enabling only late-stage detection. Earlier AKI detection is an important component of reducing renal morbidity, and mortality in the critical care population. New biomarkers cystatin C, kidney injury molecule-1(KIM-1), neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18 (IL-18), promised earlier diagnosis, but results were not convincing when validated in independent studies. Proteome analysis, by capillary electrophoresis mass spectrometry (CE-MS), has enabled the identification and validation of a novel urinary biomarker panel for AKI detection. However, CE-MS is slow, expensive, and inappropriate for routine intensive care unit (ICU) use. This proposal will establish an alternative analytical platform to assess our novel biomarker panel, which is efficient, inexpensive and acceptable for routine ICU use. Two platforms - matrix assisted laser desorption/ionisation-time of flight (MALDI-TOF) and multiple reaction monitoring (MRM) triple-quad-MS - will be explored as dual development strategy to optimise outcome.</gtr:technicalSummary><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>784274</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>60CA3F4E-B013-451D-8969-142633E8B4C7</gtr:id><gtr:title>Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study.</gtr:title><gtr:parentPublicationTitle>Critical care (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bd160eaba869ffae6caa2d415c05c6a"><gtr:id>4bd160eaba869ffae6caa2d415c05c6a</gtr:id><gtr:otherNames>Metzger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1364-8535</gtr:issn><gtr:outcomeId>585d500bc3e9f6.80320407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEFAF988-C35A-46D4-93EC-424A4225038F</gtr:id><gtr:title>Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.</gtr:title><gtr:parentPublicationTitle>Electrophoresis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/968cbafb0eaf4cbf72a90fea95cb5cdc"><gtr:id>968cbafb0eaf4cbf72a90fea95cb5cdc</gtr:id><gtr:otherNames>Stalmach A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0173-0835</gtr:issn><gtr:outcomeId>pm_15310_20_23512263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4D398F9-8CFA-4815-BDAA-58A4EED7FB81</gtr:id><gtr:title>Proteomic biomarkers for the early detection of acute kidney injury.</gtr:title><gtr:parentPublicationTitle>Prilozi</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d6a9eb833f1d7209d487553e7bd224f"><gtr:id>3d6a9eb833f1d7209d487553e7bd224f</gtr:id><gtr:otherNames>Herget-Rosenthal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0351-3254</gtr:issn><gtr:outcomeId>pm_15310_20_22952093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C861A75-9D7C-47C7-B987-F0A42CD2513F</gtr:id><gtr:title>Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/968cbafb0eaf4cbf72a90fea95cb5cdc"><gtr:id>968cbafb0eaf4cbf72a90fea95cb5cdc</gtr:id><gtr:otherNames>Stalmach A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5675dcb337787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C50EE3CC-065F-48F9-8C3D-D072F69CD650</gtr:id><gtr:title>Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c69d4ca14dba2bc7411d6c2a9a24c8"><gtr:id>f5c69d4ca14dba2bc7411d6c2a9a24c8</gtr:id><gtr:otherNames>Albalat A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>pm_15310_20_23943474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>786F9F98-7998-4BD9-8B81-9042DADEF9D2</gtr:id><gtr:title>Development of a MALDI MS-based platform for early detection of acute kidney injury.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f1749b2dd94465270a1e93d45412c5d"><gtr:id>3f1749b2dd94465270a1e93d45412c5d</gtr:id><gtr:otherNames>Carrick E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>585d694be73b97.33825776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0FCE21F-D095-4F65-A0CC-951B6979BAAE</gtr:id><gtr:title>How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb6f2594dcb520405b28fec2f92483a6"><gtr:id>cb6f2594dcb520405b28fec2f92483a6</gtr:id><gtr:otherNames>Mischak H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>pm_15310_20_22821927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A26294F-5903-4CE6-BE41-86B61CB631C9</gtr:id><gtr:title>Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.</gtr:title><gtr:parentPublicationTitle>Bioanalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c69d4ca14dba2bc7411d6c2a9a24c8"><gtr:id>f5c69d4ca14dba2bc7411d6c2a9a24c8</gtr:id><gtr:otherNames>Albalat A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-6180</gtr:issn><gtr:outcomeId>pm_540e174e1744133a8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24C4CC6C-DF84-40F0-A70F-517DED78632C</gtr:id><gtr:title>A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01adfde682e62b8e29303b95200a1840"><gtr:id>01adfde682e62b8e29303b95200a1840</gtr:id><gtr:otherNames>Molin L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>pm_15310_20_22842158</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000791</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>